Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-922-0718
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees118
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions
What is Gossamer Bio's stock symbol?
Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."
How were Gossamer Bio's earnings last quarter?
Gossamer Bio Inc (NASDAQ:GOSS) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.74) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.18. View Gossamer Bio's Earnings History.
When is Gossamer Bio's next earnings date?
What price target have analysts set for GOSS?
5 equities research analysts have issued 12-month target prices for Gossamer Bio's stock. Their predictions range from $27.00 to $30.00. On average, they expect Gossamer Bio's stock price to reach $29.25 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price. View Analyst Price Targets for Gossamer Bio.
What is the consensus analysts' recommendation for Gossamer Bio?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gossamer Bio.
Has Gossamer Bio been receiving favorable news coverage?
Media stories about GOSS stock have been trending positive on Sunday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gossamer Bio earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Gossamer Bio.
Are investors shorting Gossamer Bio?
Gossamer Bio saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 3,409,000 shares, an increase of 38.6% from the June 30th total of 2,459,700 shares. Based on an average daily volume of 201,500 shares, the days-to-cover ratio is currently 16.9 days. Approximately 13.7% of the company's stock are short sold. View Gossamer Bio's Current Options Chain.
Who are some of Gossamer Bio's key competitors?
Some companies that are related to Gossamer Bio include GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Alkermes (ALKS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR) and The Medicines (MDCO).
What other stocks do shareholders of Gossamer Bio own?
Who are Gossamer Bio's key executives?
Gossamer Bio's management team includes the folowing people:
- Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
- Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
- Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
- Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
- Dr. Jakob Dupont, Chief Medical Officer (Age 54)
When did Gossamer Bio IPO?
(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.
When did the company's lock-up period expire?
Gossamer Bio's lock-up period expired on Wednesday, August 7th. Gossamer Bio had issued 17,250,000 shares in its public offering on February 8th. The total size of the offering was $276,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Who are Gossamer Bio's major shareholders?
Gossamer Bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.47%), Artal Group S.A. (2.44%), BlackRock Inc. (1.97%), Victory Capital Management Inc. (1.47%), Citadel Advisors LLC (1.41%) and Jennison Associates LLC (1.00%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Russell J Cox and Waage Christian. View Institutional Ownership Trends for Gossamer Bio.
Which major investors are selling Gossamer Bio stock?
GOSS stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace North America L.P., Samsara BioCapital LLC, Artal Group S.A., Citadel Advisors LLC, Cormorant Asset Management LP, Tiverton Asset Management LLC and Flinton Capital Management LLC. View Insider Buying and Selling for Gossamer Bio.
Which major investors are buying Gossamer Bio stock?
GOSS stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Vanguard Group Inc., Alps Advisors Inc., Point72 Asset Management L.P., Victory Capital Management Inc., Nuveen Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Russell J Cox and Waage Christian. View Insider Buying and Selling for Gossamer Bio.
How do I buy shares of Gossamer Bio?
Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gossamer Bio's stock price today?
One share of GOSS stock can currently be purchased for approximately $17.43.
How big of a company is Gossamer Bio?
Gossamer Bio has a market capitalization of $1.15 billion. The company earns $-146,970,000.00 in net income (profit) each year or ($22.59) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.View Additional Information About Gossamer Bio.
What is Gossamer Bio's official website?
How can I contact Gossamer Bio?
Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.
MarketBeat Community Rating for Gossamer Bio (NASDAQ GOSS)
MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote "Outperform" if you believe GOSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
